Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung
Background and Objectives Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death‐ligand 1 (PD‐L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear. Methods Twenty‐six patients with...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2018-06, Vol.117 (7), p.1563-1569 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1569 |
|---|---|
| container_issue | 7 |
| container_start_page | 1563 |
| container_title | Journal of surgical oncology |
| container_volume | 117 |
| creator | Imanishi, Naoko Hirai, Ayako Yoneda, Kazue Shimajiri, Shohei Kuwata, Taiji Tashima, Yuko Takeuchi, Masahiro Iwai, Yoshiko Ichiki, Yoshinobu Tanaka, Fumihiro |
| description | Background and Objectives
Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death‐ligand 1 (PD‐L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear.
Methods
Twenty‐six patients with surgically resected PPC were retrospectively reviewed. Immuno‐histochemical staining was used to detect PD‐L1 expression, and PD‐L1 status was classified into “high” or “low” according to the percentage of tumor cells (TCs) expressing PD‐L1 (tumor proportion score, TPS).
Results
PD‐L1 expression was positive in 20 (76.9%) patients at the cut‐off TPS value of 1%. A receiver‐operating characteristic (ROC) analysis showed that the optimal cut‐off value was 15% for prediction of cancer‐specific death with the area under ROC curve of 0.701 (P = 0.107). High PD‐L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P = 0.046) as well as a favorable cancer‐specific survival (88.9% vs 37.5% at 5 years; P = 0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD‐L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054‐1.200]; P = 0.084).
Conclusions
PD‐L1 expression was positive in most PPC cases, and high PD‐L1 expression may predict a favorable prognosis in resected PPC. |
| doi_str_mv | 10.1002/jso.25041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2020482508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2062919907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4191-c49e5046d470dff77c21dacc611d844c8b00ef8ee29fbeba73b99cb9c71aa72e3</originalsourceid><addsrcrecordid>eNp1kM9Kw0AQhxdRbK0efAFZ8NIe0s5uY5I9Sv1PoQXtOWw2kzYlycbdBu3NR_AZfRJXUz0IXmYY5uPHj4-QUwZDBsBHa6uH_AJ8tke6DETgCRDRPum6H_f8UECHHFm7BgAhAv-QdLgIgAXjcZcs5kYvjSxLTGmKcrP6eHsv8qWsUspof37lzikbUHytDVqb64rmFa0L1KU29SpXVEmj8kqXkuqMblZIi6ZaHpODTBYWT3a7RxY310-TO286u72fXE495TPB3BToagepH0KaZWGoOEulUgFjaeT7KkoAMIsQucgSTGQ4ToRQiVAhkzLkOO6RfptbG_3coN3EZW4VFoWsUDc25sDBj5yayKHnf9C1bkzl2jkq4IIJAaGjBi2ljLbWYBbXJi-l2cYM4i_XsXMdf7t27NkusUmcvl_yR64DRi3wkhe4_T8pfnictZGfuQeJSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2062919907</pqid></control><display><type>article</type><title>Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Imanishi, Naoko ; Hirai, Ayako ; Yoneda, Kazue ; Shimajiri, Shohei ; Kuwata, Taiji ; Tashima, Yuko ; Takeuchi, Masahiro ; Iwai, Yoshiko ; Ichiki, Yoshinobu ; Tanaka, Fumihiro</creator><creatorcontrib>Imanishi, Naoko ; Hirai, Ayako ; Yoneda, Kazue ; Shimajiri, Shohei ; Kuwata, Taiji ; Tashima, Yuko ; Takeuchi, Masahiro ; Iwai, Yoshiko ; Ichiki, Yoshinobu ; Tanaka, Fumihiro</creatorcontrib><description>Background and Objectives
Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death‐ligand 1 (PD‐L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear.
Methods
Twenty‐six patients with surgically resected PPC were retrospectively reviewed. Immuno‐histochemical staining was used to detect PD‐L1 expression, and PD‐L1 status was classified into “high” or “low” according to the percentage of tumor cells (TCs) expressing PD‐L1 (tumor proportion score, TPS).
Results
PD‐L1 expression was positive in 20 (76.9%) patients at the cut‐off TPS value of 1%. A receiver‐operating characteristic (ROC) analysis showed that the optimal cut‐off value was 15% for prediction of cancer‐specific death with the area under ROC curve of 0.701 (P = 0.107). High PD‐L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P = 0.046) as well as a favorable cancer‐specific survival (88.9% vs 37.5% at 5 years; P = 0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD‐L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054‐1.200]; P = 0.084).
Conclusions
PD‐L1 expression was positive in most PPC cases, and high PD‐L1 expression may predict a favorable prognosis in resected PPC.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.25041</identifier><identifier>PMID: 29601633</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adenoma, Pleomorphic - metabolism ; Adenoma, Pleomorphic - pathology ; Adenoma, Pleomorphic - surgery ; Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen - metabolism ; Biomarkers, Tumor - metabolism ; Cancer ; Cancer surgery ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - surgery ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Humans ; Ligands ; Lung cancer ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Male ; Medical prognosis ; Middle Aged ; PD‐L1 ; Prognosis ; pulmonary pleomorphic carcinoma ; Retrospective Studies ; Survival Rate</subject><ispartof>Journal of surgical oncology, 2018-06, Vol.117 (7), p.1563-1569</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4191-c49e5046d470dff77c21dacc611d844c8b00ef8ee29fbeba73b99cb9c71aa72e3</citedby><cites>FETCH-LOGICAL-c4191-c49e5046d470dff77c21dacc611d844c8b00ef8ee29fbeba73b99cb9c71aa72e3</cites><orcidid>0000-0001-7142-2743</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.25041$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.25041$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29601633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imanishi, Naoko</creatorcontrib><creatorcontrib>Hirai, Ayako</creatorcontrib><creatorcontrib>Yoneda, Kazue</creatorcontrib><creatorcontrib>Shimajiri, Shohei</creatorcontrib><creatorcontrib>Kuwata, Taiji</creatorcontrib><creatorcontrib>Tashima, Yuko</creatorcontrib><creatorcontrib>Takeuchi, Masahiro</creatorcontrib><creatorcontrib>Iwai, Yoshiko</creatorcontrib><creatorcontrib>Ichiki, Yoshinobu</creatorcontrib><creatorcontrib>Tanaka, Fumihiro</creatorcontrib><title>Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Background and Objectives
Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death‐ligand 1 (PD‐L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear.
Methods
Twenty‐six patients with surgically resected PPC were retrospectively reviewed. Immuno‐histochemical staining was used to detect PD‐L1 expression, and PD‐L1 status was classified into “high” or “low” according to the percentage of tumor cells (TCs) expressing PD‐L1 (tumor proportion score, TPS).
Results
PD‐L1 expression was positive in 20 (76.9%) patients at the cut‐off TPS value of 1%. A receiver‐operating characteristic (ROC) analysis showed that the optimal cut‐off value was 15% for prediction of cancer‐specific death with the area under ROC curve of 0.701 (P = 0.107). High PD‐L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P = 0.046) as well as a favorable cancer‐specific survival (88.9% vs 37.5% at 5 years; P = 0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD‐L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054‐1.200]; P = 0.084).
Conclusions
PD‐L1 expression was positive in most PPC cases, and high PD‐L1 expression may predict a favorable prognosis in resected PPC.</description><subject>Adenoma, Pleomorphic - metabolism</subject><subject>Adenoma, Pleomorphic - pathology</subject><subject>Adenoma, Pleomorphic - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>B7-H1 Antigen - metabolism</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Cancer surgery</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Ligands</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>PD‐L1</subject><subject>Prognosis</subject><subject>pulmonary pleomorphic carcinoma</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9Kw0AQhxdRbK0efAFZ8NIe0s5uY5I9Sv1PoQXtOWw2kzYlycbdBu3NR_AZfRJXUz0IXmYY5uPHj4-QUwZDBsBHa6uH_AJ8tke6DETgCRDRPum6H_f8UECHHFm7BgAhAv-QdLgIgAXjcZcs5kYvjSxLTGmKcrP6eHsv8qWsUspof37lzikbUHytDVqb64rmFa0L1KU29SpXVEmj8kqXkuqMblZIi6ZaHpODTBYWT3a7RxY310-TO286u72fXE495TPB3BToagepH0KaZWGoOEulUgFjaeT7KkoAMIsQucgSTGQ4ToRQiVAhkzLkOO6RfptbG_3coN3EZW4VFoWsUDc25sDBj5yayKHnf9C1bkzl2jkq4IIJAaGjBi2ljLbWYBbXJi-l2cYM4i_XsXMdf7t27NkusUmcvl_yR64DRi3wkhe4_T8pfnictZGfuQeJSw</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Imanishi, Naoko</creator><creator>Hirai, Ayako</creator><creator>Yoneda, Kazue</creator><creator>Shimajiri, Shohei</creator><creator>Kuwata, Taiji</creator><creator>Tashima, Yuko</creator><creator>Takeuchi, Masahiro</creator><creator>Iwai, Yoshiko</creator><creator>Ichiki, Yoshinobu</creator><creator>Tanaka, Fumihiro</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7142-2743</orcidid></search><sort><creationdate>20180601</creationdate><title>Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung</title><author>Imanishi, Naoko ; Hirai, Ayako ; Yoneda, Kazue ; Shimajiri, Shohei ; Kuwata, Taiji ; Tashima, Yuko ; Takeuchi, Masahiro ; Iwai, Yoshiko ; Ichiki, Yoshinobu ; Tanaka, Fumihiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4191-c49e5046d470dff77c21dacc611d844c8b00ef8ee29fbeba73b99cb9c71aa72e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenoma, Pleomorphic - metabolism</topic><topic>Adenoma, Pleomorphic - pathology</topic><topic>Adenoma, Pleomorphic - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>B7-H1 Antigen - metabolism</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Cancer surgery</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Ligands</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>PD‐L1</topic><topic>Prognosis</topic><topic>pulmonary pleomorphic carcinoma</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imanishi, Naoko</creatorcontrib><creatorcontrib>Hirai, Ayako</creatorcontrib><creatorcontrib>Yoneda, Kazue</creatorcontrib><creatorcontrib>Shimajiri, Shohei</creatorcontrib><creatorcontrib>Kuwata, Taiji</creatorcontrib><creatorcontrib>Tashima, Yuko</creatorcontrib><creatorcontrib>Takeuchi, Masahiro</creatorcontrib><creatorcontrib>Iwai, Yoshiko</creatorcontrib><creatorcontrib>Ichiki, Yoshinobu</creatorcontrib><creatorcontrib>Tanaka, Fumihiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imanishi, Naoko</au><au>Hirai, Ayako</au><au>Yoneda, Kazue</au><au>Shimajiri, Shohei</au><au>Kuwata, Taiji</au><au>Tashima, Yuko</au><au>Takeuchi, Masahiro</au><au>Iwai, Yoshiko</au><au>Ichiki, Yoshinobu</au><au>Tanaka, Fumihiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>117</volume><issue>7</issue><spage>1563</spage><epage>1569</epage><pages>1563-1569</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background and Objectives
Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death‐ligand 1 (PD‐L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear.
Methods
Twenty‐six patients with surgically resected PPC were retrospectively reviewed. Immuno‐histochemical staining was used to detect PD‐L1 expression, and PD‐L1 status was classified into “high” or “low” according to the percentage of tumor cells (TCs) expressing PD‐L1 (tumor proportion score, TPS).
Results
PD‐L1 expression was positive in 20 (76.9%) patients at the cut‐off TPS value of 1%. A receiver‐operating characteristic (ROC) analysis showed that the optimal cut‐off value was 15% for prediction of cancer‐specific death with the area under ROC curve of 0.701 (P = 0.107). High PD‐L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P = 0.046) as well as a favorable cancer‐specific survival (88.9% vs 37.5% at 5 years; P = 0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD‐L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054‐1.200]; P = 0.084).
Conclusions
PD‐L1 expression was positive in most PPC cases, and high PD‐L1 expression may predict a favorable prognosis in resected PPC.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29601633</pmid><doi>10.1002/jso.25041</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7142-2743</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2018-06, Vol.117 (7), p.1563-1569 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2020482508 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenoma, Pleomorphic - metabolism Adenoma, Pleomorphic - pathology Adenoma, Pleomorphic - surgery Adult Aged Aged, 80 and over B7-H1 Antigen - metabolism Biomarkers, Tumor - metabolism Cancer Cancer surgery Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Female Follow-Up Studies Gene Expression Regulation, Neoplastic Humans Ligands Lung cancer Lung Neoplasms - metabolism Lung Neoplasms - pathology Lung Neoplasms - surgery Male Medical prognosis Middle Aged PD‐L1 Prognosis pulmonary pleomorphic carcinoma Retrospective Studies Survival Rate |
| title | Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T03%3A03%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Programmed%20death%E2%80%90ligand%201%20(PD%E2%80%90L1)%20expression%20in%20pleomorphic%20carcinoma%20of%20the%20lung&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Imanishi,%20Naoko&rft.date=2018-06-01&rft.volume=117&rft.issue=7&rft.spage=1563&rft.epage=1569&rft.pages=1563-1569&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.25041&rft_dat=%3Cproquest_cross%3E2062919907%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2062919907&rft_id=info:pmid/29601633&rfr_iscdi=true |